Our results show that this optimized double-edged LUV-TRAIL formulation harbors an enhanced exceptional cytotoxic ability and could be potentially useful to improve anti-tumor therapy against TRAIL-resistant cancers. The gene discussed is TNFSF10; the disease is neoplasm.